A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

Published:2014-07-29 Issue:6 Volume:111 Page:1072-1079
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cheah C Y,Herbert K E,O'Rourke K,Kennedy G A,George A,Fedele P L,Gilbertson M,Tan S Y,Ritchie D S,Opat S S,Prince H M,Dickinson M,Burbury K,Wolf M,Januszewicz E H,Tam C S,Westerman D A,Carney D A,Harrison S J,Seymour J F

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014405.pdf

Reference44 articles.

1. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116 (18): 4283–4290.

2. Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG (2000) Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol 45 (3): 259–264.

3. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. J Clin Oncol 27 (1): 114–119.

4. Bjorkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 18 (6): 1085–1089.

5. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113 (17): 3896–3902.

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data;Blood Cancer Journal;2024-07-04

2. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma;JCO Oncology Practice;2024-06

3. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma;Blood Advances;2024-03-18

4. Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma;Case Reports in Hematology;2024-02-22

5. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601;Annals of Hematology;2024-01-27